KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Land & Improvements (2016 - 2018)

Teva Pharmaceutical Industries (TEVA) has disclosed Land & Improvements for 6 consecutive years, with $351.0 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Land & Improvements changed N/A year-over-year to $351.0 million, compared with a TTM value of $351.0 million through Dec 2018, changed N/A, and an annual FY2018 reading of $351.0 million, changed N/A over the prior year.
  • Land & Improvements was $351.0 million for Q4 2018 at Teva Pharmaceutical Industries, down from $361.0 million in the prior quarter.
  • Across five years, Land & Improvements topped out at $439.0 million in Q4 2016 and bottomed at $351.0 million in Q4 2018.
  • Average Land & Improvements over 4 years is $378.4 million, with a median of $372.0 million recorded in 2014.
  • The sharpest move saw Land & Improvements dropped 16.59% in 2014, then increased 11.42% in 2016.
  • Year by year, Land & Improvements stood at $372.0 million in 2014, then grew by 5.91% to $394.0 million in 2015, then increased by 11.42% to $439.0 million in 2016, then decreased by 20.05% to $351.0 million in 2018.
  • Business Quant data shows Land & Improvements for TEVA at $351.0 million in Q4 2018, $361.0 million in Q3 2018, and $374.0 million in Q2 2018.